Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04344769 · ClinicalTrials.gov registry record
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A clinical trial of Autosomal Dominant Polycystic Kidney Disease, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT04344769: Recruiting study of Autosomal Dominant Polycystic Kidney Disease, sponsored by Mayo Clinic.
NCT04344769 is a study of Autosomal Dominant Polycystic Kidney Disease that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 40 participants, below the 157-participant average among 9 other Autosomal Dominant Polycystic Kidney Disease trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04344769, a study of Autosomal Dominant Polycystic Kidney Disease, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to characterize oxidative stress and the Nrf2 antioxidant response in early stages of Autosomal Dominant Polycystic Kidney Disease (ADPKD), while identifying candidate biomarkers.
Primary Outcome
Determination of common biomarkers of oxidative damage including but not limited to: 8-oxodeoxyguanosine, F2-isoprostanes, from urine and plasma samples
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-10-04 |
| Est. Completion | 2026-12 |
What NCT04344769 shows while recruiting
NCT04344769 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 157-participant average among 9 other Autosomal Dominant Polycystic Kidney Disease trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Autosomal Dominant Polycystic Kidney Disease appearing as the primary indexed condition, and to 0 interventions.
NCT04344769 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04344769 about?
NCT04344769 is a clinical study titled "Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)". The purpose of this study is to characterize oxidative stress and the Nrf2 antioxidant response in early stages of Autosomal Dominant Polycystic Kidney Disease (ADPKD), while identifying candidate biomarkers.
What is the current status of trial NCT04344769?
This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2019-10-04. Estimated completion is 2026-12.
What conditions does trial NCT04344769 study?
This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney Disease.
Who is sponsoring clinical trial NCT04344769?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04344769 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autosomal Dominant Polycystic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04344769's enrollment target sits among peer trials
40 7th of 9 higher than 2 of 9 other Autosomal Dominant Polycystic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autosomal Dominant Polycystic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NOX4 and Related Biomarkers in ADPKD
RECRUITING
-
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RECRUITING · Phase 2
-
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
RECRUITING · Phase 1
-
A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
ACTIVE NOT RECRUITING
-
Intrarenal Microvasculature in ADPKD
ACTIVE NOT RECRUITING
-
Role of ROS and cAMP-PKA Biomarkers in ADPKD
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI